RxDoctor Payments Data

Dominique El-Khawand, MD

Urogynecology and Reconstructive Pelvic Surgery · York, PANPI 1841234580

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (47.7%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Medtronic at 53.3% of the total. 2025 is the largest year on record at $1,695, 4.4 times the $384 reported in 2019.

$4,200in general payments, 2019–2025

Across 32 payments — averaging $131.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Valencia Technologies Corporation$669
  • Boston Scientific$590
  • Coloplast$393
  • Intuitive Surgical$310
$20,000in ownership & investment interests, 2019–2025

Across 4 payments — averaging $5000.00 each. An ownership or investment interest held by the physician or an immediate family member.

  • Valencia Technologies Corporation$20K

What the payments were for

  • Travel & lodging$2,00248%
  • Food & beverage$1,88845%
  • Gifts$3107%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,200 in reported general payments places this provider in the 60th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$125,797
Medicare patients
343
Services billed
1,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron440$320,786
GemtesaVibegron407$313,354
Mirabegron ErMirabegron51$29,010
Trospium Chloride ErTrospium Chloride91$17,232
Estradiol112$7,143
Methenamine Hippurate37$3,292
Darifenacin ErDarifenacin Hydrobromide24$3,043
Fesoterodine Fumarate ErFesoterodine Fumarate18$1,333
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst72$656
Trospium Chloride18$397
Ciprofloxacin Hcl30$52
Cephalexin13$23
Fluconazole11$17

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →